Clazakizumab ELISA Kit

Clazakizumab, a humanized anti–IL-6 mAb, is used in the phase II clinical trial for the treatment of RA patients. It has also been evaluated for the treatment of non-small cell lung cancer (NSCLC) and patients with head and neck cancer.

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.